Table 1.
Pharmacokinetics of R- and S-methadone in the absence or presence of telaprevir
| Pharmacokinetic parametera | Value(s)b |
LS mean ratio (90% CI) for methadone + telaprevir vs methadone only | |
|---|---|---|---|
| Individualized methadone therapy (reference [day −1]) | Individualized methadone therapy + telaprevir (750 mg q8h) (test [day 7]) | ||
| R-Methadone | |||
| n | 17 | 15 | |
| tmax (h) | 2.5 (1.5, 16.0) | 3.0 (1.5, 4.0) | |
| Cmin (ng/ml) | 139.2 ± 45.31 | 93.47 ± 28.63 | 0.69 (0.64, 0.75) |
| Cmax (ng/ml) | 257.7 ± 92.69 | 189.8 ± 113.8 | 0.71 (0.66, 0.76) |
| AUC0–24 (ng · h/ml) | 4,334 ± 1,542 | 2,991 ± 959.6 | 0.71 (0.66, 0.76) |
| S-Methadone | |||
| n | 17 | 15 | |
| tmax (h) | 2.5 (1.5, 16.0) | 2.5 (1.0–4.0) | |
| Cmin (ng/ml) | 132.8 ± 57.12 | 81.97 ± 42.79 | 0.60 (0.54, 0.67) |
| Cmax (ng/ml) | 301.8 ± 114.4 | 211.9 ± 145.3 | 0.65 (0.60, 0.71) |
| AUC0–24 (ng · h/ml) | 4,562 ± 1,982 | 2,941 ± 1,378 | 0.64 (0.58, 0.70) |
| S-Methadone vs R-methadone AUC0–24 | 0.90 (0.86, 0.94) | ||
a
n, number of subjects.
b
tmax data are shown as median (range); all other parameters are shown as mean ± standard deviation.